CXCL10 and pulmonary arterial hypertension: By activating the core signaling axis of type I immune responses, it synergistically induces an expression cascade of key effector factors including CXCL10, IL-12,and IFN-γ, thereby enhancing specific chemotaxis and infiltration of lymphocytes into the pulmonary vascular wall and ultimately exacerbating the pathological progression of PAH.